Agios Pharmaceuticals Inc 2022 SR
The report highlights Agios Pharmaceuticals' transition to a company solely focused on genetically defined diseases following the divestment of its oncology business in 2021. Key achievements include the development of the first FDA-approved therapy for pyruvate kinase (PK) deficiency and a $298.5 million investment in research and development. The company launched the 'Reimagining Work' pilot program to enhance workplace flexibility and achieved AAALAC accreditation for its animal research facility. Additionally, Agios demonstrated a strong commitment to diversity, with women representing 55% of executive and senior management roles and 38% of the Board of Directors.
Company: Agios Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2022
Type: SR
Pages: 43
Agios Pharmaceuticals Inc
ESG Report
The report highlights Agios Pharmaceuticals' transition to a company solely focused on genetically defined diseases following the divestment of its oncology business in 2021. Key achievements include the development of the first FDA-approved therapy for pyruvate kinase (PK) deficiency and a $298.5 million investment in research and development. The company launched the 'Reimagining Work' pilot program to enhance workplace flexibility and achieved AAALAC accreditation for its animal research facility. Additionally, Agios demonstrated a strong commitment to diversity, with women representing 55% of executive and senior management roles and 38% of the Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Jan 1, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities